I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Thomas Kearns, Jr. Biography and Net Worth

Director of FibroGen

Thomas F. Kearns, Jr. has served on our board of directors since November 1996, as lead independent director from June 2017 until August 2019, and as Chairperson of our board of directors from August 2019 until January 2020. Mr. Kearns is a retired Partner of The Bear Stearns Companies, Inc., an investment banking firm, where he was an investment banker in the healthcare area from 1974 until 1987. Prior to his career at Bear Stearns, Mr. Kearns worked for Merrill Lynch, an investment banking firm, from January 1959 until August 1969. Mr. Kearns was Chairman of the National Advisory Board of Carolina Performing Arts at the University of North Carolina from 2008 until 2015. Mr. Kearns was a Trustee of the University of North Carolina Foundation and Endowment Fund for 16 years. He served on the board of directors of Biomet Inc. from January 1980 until May 2005, and he served on the board of directors of Franklin Street Partners from 2013 until 2018. He received his B.A. in History from the University of North Carolina.

What is Thomas F. Kearns, Jr.'s net worth?: The estimated net worth of Thomas F. Kearns, Jr. is at least $66,465.60 as of March 11th, 2021. Mr. Kearns, Jr. owns 166,164 shares of FibroGen stock worth more than $66,466 as of December 22nd. This net worth evaluation does not reflect any other assets that Mr. Kearns, Jr. may own. Learn More about Thomas F. Kearns, Jr.'s net worth.
How do I contact Thomas F. Kearns, Jr.?: The corporate mailing address for Mr. Kearns, Jr. and other FibroGen executives is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. FibroGen can also be reached via phone at (415) 978-1200 and via email at [email protected]. Learn More on Thomas F. Kearns, Jr.'s contact information.
Has Thomas F. Kearns, Jr. been buying or selling shares of FibroGen?: Thomas F. Kearns, Jr. has not been actively trading shares of FibroGen during the past quarter. Most recently, Thomas F. Kearns, Jr. sold 13,100 shares of the business's stock in a transaction on Wednesday, September 15th. The shares were sold at an average price of $11.58, for a transaction totalling $151,698.00. Learn More on Thomas F. Kearns, Jr.'s trading history.
Who are FibroGen's active insiders?: FibroGen's insider roster includes Pat Cotroneo (CFO), Thomas Kearns, Jr. (Director), and Thane Wettig (Insider). Learn More on FibroGen's active insiders.
Are insiders buying or selling shares of FibroGen?: In the last year, FibroGen insiders bought shares 2 times. They purchased a total of 72,123 shares worth more than $121,383.91. The most recent insider tranaction occured on June, 12th when insider Deyaa Adib bought 22,123 shares worth more than $25,883.91. Insiders at FibroGen own 2.0% of the company. Learn More about insider trades at FibroGen.
Information on this page was last updated on 6/12/2024.

Thomas F. Kearns, Jr. Insider Trading History at FibroGen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/15/2021	Sell	13,100	$11.58	$151,698.00
3/11/2021	Sell	18,000	$35.02	$630,360.00	166,164
3/19/2020	Sell	18,000	$23.17	$417,060.00	161,464
3/12/2018	Sell	18,000	$55.00	$990,000.00	135,064
11/15/2017	Sell	18,000	$45.22	$813,960.00	156,564
6/6/2017	Sell	18,000	$28.71	$516,780.00	156,564
11/18/2016	Sell	18,000	$22.40	$403,200.00	165,564
1/21/2016	Sell	1,572	$22.08	$34,709.76	160,564
12/24/2015	Sell	7,800	$30.88	$240,864.00	162,136
11/24/2015	Sell	3,900	$29.00	$113,100.00	169,936
11/23/2015	Sell	3,900	$28.02	$109,278.00	169,936
10/21/2015	Sell	7,800	$23.83	$185,874.00	177,736

Thomas F. Kearns, Jr. Buying and Selling Activity at FibroGen

FibroGen Company Overview

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Today's Range

Now: $0.40

$0.35

$0.43

50 Day Range

MA: $0.35

$0.30

$0.42

2 Week Range

Now: $0.40

$0.18

$2.93

Volume

3,363,930 shs

Average Volume

2,111,790 shs

Market Capitalization

$40.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.82

I was wrong. Dead wrong.

From Porter & Company | Ad